1506-P: Breast Cancer as a Risk Factor for New Diabetes
Conferences
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
While diabetes is an important risk factor for breast cancer, less is known regarding whether a breast cancer diagnosis is associated with increased risk of subsequent diabetes. We therefore assessed the effect of a breast cancer diagnosis on incident diabetes, using population-level data from Danish healthcare registries during 2005-2016. Our study population comprised 33,909 women aged >50 years with new-onset breast cancer and 313,998 comparison cohort members matched by age and the breast cancer diagnosis date (index date) from the general population, all with no prior history of cancer or diabetes. Women with breast cancer and their comparison cohort members were followed for up to 12 years, to ascertain a first occurrence of glucose-lowering drug treatment or hospital-diagnosed diabetes. The hazard of breast cancer for subsequent diabetes was computed using Cox proportional hazard models, adjusting for a range of comorbidities and medications. Mean age at baseline was 66.0 in cancer patients and 65.8 in the comparison cohort. The rate of developing diabetes was 15% greater in breast cancer patients than in the comparison cohort during the first year after breast cancer diagnosis/index date (adjusted hazard ratio [aHR] 1.15, 95% confidence interval [CI] 1.01-1.30). During total follow-up (median 5.2 years), the diabetes rate was 23% greater in women with breast cancer (aHR 1.23, 95% CI 1.16-1.30), corresponding to 8.4 new cases of diabetes per 1000 women per year vs. 6.8 among comparison cohort members. Breast cancer patients were more likely to be treated with an insulin-based regimen (4.8%) compared to comparison cohort members (2.1%). Our findings suggest that breast cancer is an important risk factor for diabetes. Breast cancer patients may benefit from targeted screening for diabetes and counseling regarding risk factor modification.DisclosureR. Shah: None. H. Gerstein: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Research Support; Self; AstraZeneca, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. Other Relationship; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi. S.K. Szépligeti: None. H.T. Sôrensen: None. R.W. Thomsen: None.
